ERS 2015: Updated Diagnostic and Treatment Optimization Tactics to Improve Quality of Life in Patients with IPF
This CME activity will focus on essential sessions and new and emerging data presented at the European Respiratory Society (ERS) International Congress 2015. The focus of this program will be to provide optimal treatment plans to improve quality of life in patients with idiopathic pulmonary fibrosis (IPF).
This CME program will bring physicians up to date on current clinical trial data, and how they can apply the information into their practice. Expert faculty will discuss optimal treatment plans for patients who suffer from IPF.
Pulmonologists, respiratory specialists, primary care physicians, and other healthcare clinicians responsible for the care of patients with IPF.
Upon completion of this activity, participants will be able to:
- Describe treatment guidelines and therapeutic recommendations in IPF to ensure early recognition, diagnosis, and appropriate treatment selection.
- Develop personalized treatment plans to effectively address risk management, comorbidities, and lung function to improve the quality of life in patients with IPF.
Gerard J. Criner, MD
Fernando J. Martinez, MD
Kevin K. Brown, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Gerald J. Criner, MD
Nothing to disclose.
Fernando J. Martinez, MD
Consultant/Advisor: Amgen Inc.; AstraZeneca; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc; Forest Laboratories, Inc; Genentech, Inc; GlaxoSmithKline plc; Ikaria, Inc.
Grant/Research Support: AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc; Forest Laboratories, Inc; GlaxoSmithKline plc; Stromedix; Takeda Pharmaceutical Company Limited
Royalties/Patents: UpToDate, Inc.
Speakers Bureau: Annenberg Media; California Society of Allergy, Asthma, and Immunology; Falco; Haymarket Media Group; Miller; National Association for Continuing Education; University of Michigan; Western Society of Allergy, Asthma, and Immunology
Kevin K. Brown, MD
Consultant/Advisor: Actelion Pharmaceuticals US, Inc; Almirall, S.A.; Altitude Pharma, Inc.; Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc; Celgen Corporation; Centocor; FibroGen, Inc.; Galecto Biotech AB; Genzyme Corporation, a Sanofi company; Gilead; GlaxoSmithKline plc; MedImmune, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Promedior, Inc.; Roche/Genentech, Inc.; Stromedix; Veracyte, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc; Amgen Inc.; National Heart, Lung, and Blood Institute; Gilead
Non-Faculty: Sandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course Open Date: December 16, 2015 | Course Expiration Date: December 15, 2016
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician